Welcome to our dedicated page for CME Group SEC filings (Ticker: CME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking the moving parts behind a global derivatives powerhouse can feel overwhelming. CME Group鈥檚 annual reports stretch past 200 pages, and its Form 4 insider notices drop without warning鈥攐ften right before rate-sensitive futures rallies. If you have ever asked, 鈥淲here can I find CME Group鈥檚 quarterly earnings report 10-Q filing?鈥� or 鈥淗ow do I decode clearinghouse risk in the 10-K?鈥�, you are not alone.
Stock Titan solves this complexity. Our AI-powered summaries turn dense disclosures into plain-English briefs鈥攕o understanding CME Group SEC documents with AI becomes routine. Need CME Group insider trading Form 4 transactions? We stream CME Group Form 4 insider transactions real-time, flagging executive stock transactions the moment they reach EDGAR. Looking for revenue per contract or margin requirements? The platform highlights them automatically within the CME Group annual report 10-K simplified, while our dashboard links every footnote to the relevant accounting rule.
You will find every filing type鈥�10-K, 10-Q, 8-K, DEF 14A, S-8鈥攊ndexed and searchable. Click the 10-Q tab for a concise CME Group earnings report filing analysis; open any 8-K for CME Group 8-K material events explained in seconds. The proxy section answers, 鈥淲hat鈥檚 inside the CME Group proxy statement executive compensation?鈥� by extracting pay ratio, incentive targets, and peer comparisons. AG真人官方-time alerts keep you ahead when material events hit or when directors buy shares. Whether you monitor fee trends, hedge fund positioning, or just want CME Group SEC filings explained simply, Stock Titan provides the clarity professionals need鈥攁ll in one place.
CME Group director Patrick J. Mulchrone reported insider trading activity on June 25, 2025. Key details of the transaction include:
- Acquired 532 shares of Class A Common Stock at $273.03 per share through the CME Group Director Stock Plan
- Following the transaction, Mulchrone directly owns 28,485 shares
- Additionally holds 25,000 shares indirectly through spouse
The Form 4 filing indicates this was a planned acquisition under the company's director compensation program rather than an open market transaction. The filing was submitted by Jenelle Chalmers on behalf of Mulchrone on June 26, 2025, within the required reporting timeframe.
CME Group director Phyllis M. Lockett reported an acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted pursuant to the CME Group Director Stock Plan.
Following this transaction, Lockett now beneficially owns 3,640 shares directly. The filing indicates this was a planned stock grant as part of director compensation rather than an open market purchase.
- Transaction Code: A (Grant/Award)
- Ownership Form: Direct (D)
- Filing Type: Form 4 (Statement of Changes in Beneficial Ownership)
- Total Transaction Value: Approximately $145,252
This insider transaction represents routine director compensation and does not indicate any unusual trading patterns or significant changes in ownership structure.
CME Group director Deborah J. Lucas reported an acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted pursuant to the CME Group Director Stock Plan.
Following this transaction, Lucas now beneficially owns 3,888 shares directly. The filing indicates this was a routine director stock grant rather than an open market purchase.
Key Transaction Details:
- Transaction Type: Stock Award (Code A)
- Ownership Type: Direct
- Role: Director
- Total Transaction Value: $145,251.96
CME Group director Bryan T. Durkin reported the acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted pursuant to the CME Group Director Stock Plan.
Following this transaction, Durkin now beneficially owns 47,207 shares directly. The filing indicates this was a standard director compensation grant rather than an open market purchase.
Key Transaction Details:
- Transaction Type: Stock Award (Code A)
- Ownership Type: Direct
- Role: Director
- Total Value of Transaction: $145,251.96
CME Group director Daniel G. Kaye reported an acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted pursuant to the CME Group Director Stock Plan.
Following this transaction, Kaye now beneficially owns 4,200 shares directly. The filing indicates this was a planned acquisition under the company's director compensation program rather than an open market purchase.
- Transaction Type: Stock Grant (Code A)
- Reporting Person Role: Director
- Ownership Form: Direct
- Filing was submitted by Jenelle Chalmers on behalf of Daniel G. Kaye
CME Group director Charles P. Carey reported insider trading activity on June 25, 2025. The transaction involved the acquisition of 879 Class A Common Stock shares at a price of $273.03 per share through a trust, granted pursuant to the CME Group Director Stock Plan.
Following the transaction, Carey's beneficial ownership consists of:
- 5,779 shares held indirectly through trust
- 185 shares held indirectly through firm
- 0.375 shares held indirectly through partnership
The Form 4 filing indicates this was a planned acquisition under the director compensation program rather than an open market transaction. No derivative securities were involved in this transaction.
CME Group director William W. Hobert reported insider trading activity on June 25, 2025. The transaction involved the acquisition of 879 shares of Class A Common Stock at a price of $273.03 per share through the CME Group Director Stock Plan.
Following the transaction, Hobert's holdings include:
- 86,598 shares held directly
- 40,000 shares held indirectly through his firm
The transaction was executed pursuant to the company's Director Stock Plan, as amended and restated. The Form 4 was filed on behalf of Hobert by Jenelle Chalmers on June 26, 2025, within the required reporting timeframe.
CME Group director Martin J. Gepsman reported an acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted pursuant to the CME Group Director Stock Plan.
Following this transaction, Gepsman now beneficially owns a total of 25,299 shares directly. The filing indicates this was a standard director compensation grant rather than an open market purchase.
- Transaction Type: Stock Award (Code A)
- Ownership Form: Direct
- Filing Status: Individual filing
- Role: Director (non-employee)
This insider transaction represents routine director compensation and aligns with standard corporate governance practices for board member equity compensation.
CME Group Inc. (CME) filed a Form 4 disclosing that Director Howard J. Siegel acquired 879 shares of Class A common stock on 06/25/2025 at $273.03 per share under the company鈥檚 Director Stock Plan. Following the purchase, Siegel holds 47,791 shares directly and 21,873 shares indirectly through a trust. No derivative transactions or share dispositions were reported.
Form 4 filing 鈥� CME Group Inc. (CME)
Director Dennis Suskind received 532 Class A common shares on 25 Jun 2025 under the CME Group Director Stock Plan. The grant price recorded for reporting purposes is $273.03 per share, implying a total market value of roughly $145 k. Following the award, Suskind鈥檚 direct beneficial ownership rose to 3,447 shares, an increase of about 18%. No open-market purchases, sales, or derivative transactions were reported, and there is no indication of a 10b5-1 trading plan. The transaction represents routine director compensation and does not materially affect CME鈥檚 share count or capital structure.
FAQ
What is the current stock price of CME Group (CME)?
What is the market cap of CME Group (CME)?
